Overview

Treatment Of Patients With Social Anxiety Disorder

Status:
Completed
Trial end date:
2007-09-05
Target enrollment:
Participant gender:
Summary
GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Paroxetine